{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT01642758: Phase 2 Interventional Completed Beta Thalassemia Intermedia
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
2,2-DIMETHYLBUTYRIC ACID (HQK-1001) is an orally administered SCFAD (Short Chain Fatty Acid Derivative), which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. The compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia. HemaQuest Pharmaceuticals was developing HQK-1001 for the oral treatment of sickle cell anaemia and beta thalassaemia. HQK-1001 has been evaluated in phase II trials for beta thalassaemia and sickle cell anaemia.
Status:
Investigational
Source:
NCT00139672: Phase 2 Interventional Completed Irritable Bowel Syndrome
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
PD-217014 or PD-217,014, a new GABA analog was developed by Pfizer as a potent alpha(2)delta ligand of voltage-gated calcium channel, that and possessed visceral analgesic activity. This compound was undergoing phase II clinical trials for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). In addition, PD-217014 was investigated for postherpetic neuralgia treatment. However, all these studies were discontinued.
Status:
Investigational
Source:
NCT01457677: Phase 2 Interventional Completed Major Depressive Disorder
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Decoglurant is a negative allosteric modulator of the mGlu2 and mGlu receptors developed by Roche. Decoglurant was investigated in a phase 2 clinical trials in patients with major depressive disorder. Negative results were reported and the development was discontinued in 2015.
Status:
Investigational
Source:
NCT02849886: Phase 1/Phase 2 Interventional Unknown status Graft Versus Host Disease
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Rimiducid (AP1903) is a lipid-permeable tacrolimus analogue with homodimerizing activity. Rimiducid homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val). This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered proteins such as the iCD40 receptor, Fas intracellular domain or iCaspase 9 resulting in downstream signaling activation during cell therapy. Orphan designation was granted for rimiducid (AP1903) for the treatment of graft-versus-host disease.
Status:
Investigational
Source:
NCT03228524: Early Phase 1 Interventional Unknown status Brain Injuries
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
D-aspartic acid is an essential amino acid and a key ingredient in various testosterone boosting anti-estrogen supplements. D-aspartic acid is not used to build proteins; instead, it plays a role in making and releasing hormones in the body. It is an endogenous NMDA receptor agonist with similar activity to the L-isomer. D-aspartic acid also enhances the release of luteinizing hormone (LH) and testosterone. This action is mediated in the pituitary by cGMP and in the testis by cAMP, which acts as the second messengers in the signal transduction in the pituitary and testes respectively. The pituitary and testis possess a D-Aspartate racemase, which provides the necessary production of this isomer.
Status:
Investigational
Source:
NCT01381562: Phase 2 Interventional Terminated Infections, Intestinal
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Epetraborole (AN3365 or GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase. It is active against Gram-negative bacteria, including Enterobacteriaceae bearing NDM-1 and KPC carbapenemases, as well as P. aeruginosa. Epetraborole was under development for the treatment of Gram-negative bacterial infections.
Status:
Investigational
Source:
NCT01493596: Phase 1 Interventional Completed Cocaine Dependency
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
CPP-115 is a gamma-aminobutyric acid aminotransferase activator, developed by Catalyst Pharmaceutical Partners, Inc. The compound does not exhibit other GABAergic or off-target activities and is rapidly and completely orally absorbed and eliminated. In rats, CPP-115 produced inhibition of cocaine-induced increases in extracellular dopamine and in synaptic dopamine in the nucleus accumbens. CPP-115 decreased spasms in the multiple-hit rat model of infantile spasms. CPP-115 was found to have high therapeutic potential for the treatment of cocaine addiction and for a variety of epilepsies, has successfully completed a Phase I safety clinical trial, and was found to be effective in the treatment of infantile spasms (West syndrome).
Status:
Investigational
Source:
NCT01585792: Phase 3 Interventional Completed Diabetic Patients
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable GPR40 agonist. The drug was in Phase III clinical trials for the treatment of type 2 diabetes mellitus. Termination phase III development of TAK-875 for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.
Status:
Investigational
Source:
NCT01044524: Phase 1 Interventional Completed Pharmacology, Clinical
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01852604: Phase 2 Interventional Completed Chronic Hepatitis C Virus
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Samatasvir (also known as IDX 719) was developed by Idenix Pharmaceuticals as a pan-genotypic inhibitor of the hepatitis C (HCV) non-structural protein 5A (NS5A). This drug was studied in phase II clinical trials for the treatment of Hepatitis C, and Chronic Hepatitis C Infection. However, the development of samatasvir was discontinued.
